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Abstract
Germline mutations in the DNA base excision repair gene MUTYH are known to increase a 
carrier’s risk of colorectal cancer. However, the risks of other (extracolonic) cancers for MUTYH 
mutation carriers are not well defined. We identified 266 probands (91% Caucasians) with a 
MUTYH mutation (41 biallelic and 225 monoallelic) from the Colon Cancer Family Registry. 
Mutation status, sex, age, and histories of cancer from their 1,903 first- and 3,255 second-degree 
relatives, were analysed using modified segregation analysis conditioned on the ascertainment 
criteria. Compared with incidences for the general population, hazard ratios (HRs) (95% 
confidence intervals [CIs]) for biallelic MUTYH mutation carriers were: urinary bladder cancer, 
19(3.7–97); and ovarian cancer, 17(2.4–115). The HRs (95%CI) for monoallelic MUTYH 
mutation carriers were: gastric cancer, 9.3(6.7–13); hepatobiliary cancer, 4.5(2.7–7.5); endometrial 
cancer, 2.1(1.1–3.9); and breast cancer, 1.4(1.0–2.0). There was no evidence for an increased risk 
of cancers at the other sites examined (brain, pancreas, kidney or prostate). Based on the USA 
population incidences, the estimated cumulative risks (95%CI) to age 70 years for biallelic 
mutation carriers were: bladder cancer, 25%(5%–77%) for males and 8%(2%–33%) for females; 
and ovarian cancer, 14%(2%–65%). The cumulative risks (95%CI) for monoallelic mutation 
carriers were: gastric cancer, 5%(4%–7%) for males and 2.3%(1.7%–3.3%) for females; 
hepatobiliary cancer, 3%(2%–5%) for males and 1.4%(0.8%–2.3%) for females; endometrial 
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cancer, 3%(2%–6%); and breast cancer 11%(8%–16%). These unbiased estimates of both relative 
and absolute risks of extracolonic cancers for people, mostly Caucasians, with MUTYH mutations 
will be important for their clinical management.
Keywords
MUTYH; cancer risk; penetrance; MUTYH-associated polyposis
INTRODUCTION
Germline mutations in the base excision repair gene, MUTYH (MIM# 604933), cause 
increased risks of colorectal adenomas and carcinomas,1 presumably due to an increase in 
unrepaired, 8-oxoG-induced somatic G:C to T:A transversions in tumour suppressor genes.2
Biallelic (compound heterozygous or homozygous) MUTYH mutations i.e., inherited from 
both parents, occurring in 0.01–0.04% of the Caucasian population, are associated with a 18- 
to 100-fold increased risk of colorectal adenomas and cancer compared with the general 
population3-6; commonly known as MUTYH-associated polyposis (MAP) (OMIM 
#608456).1, 7 The risks of extracolonic cancers for biallelic mutation carriers, however, are 
not well defined.8-16 Several studies have reported an increased risk of duodenal cancer for 
biallelic mutation carriers.7, 12, 17, 18 Some studies have also reported an increased risk of 
bladder, ovarian, skin,12 breast,12, 19 and endometrial10, 13 cancer for biallelic mutation 
carriers; while others studies failed to confirm associations with breast11, 16, 20 or 
endometrial12, 21 cancer. Case reports of cancers of the sebaceous glands,9, 10, 22 hair 
follicles,23 stomach,18 and thyroid9, 10, 12, 15, 18 in biallelic mutation carriers have been 
documented but these studies did not determine whether the incidence of these cancers 
exceeded the expected population risk.
Monoallelic (heterozygous) MUTYH mutations, i.e., inherited from only one parent, 
occurring in 1–2% of the Caucasian population,24 are associated with a moderately 
increased risk of colorectal cancer.3, 5, 6, 25 Previous studies have reported an increased risk 
of gastric, liver, and endometrial,26 and breast cancer27-29 for monoallelic mutation carriers 
while other studies did not find statistical evidence for an increased risk of breast11, 20 or 
liver30 cancer.
Given the rarity of biallelic and monoallelic MUTYH mutation carriers, most of the previous 
studies have been underpowered to provide reliable estimates for the risks of extracolonic 
cancers. Clarity on these cancer risks is important for the clinical management of MUTYH 
mutation carriers. In the current study, using a large dataset from the Colon Cancer Family 
Registry we estimated extracolonic cancer risks for people with biallelic and monoallelic 
MUTYH mutations.
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The study sample was from the Colon Cancer Family Registry that has been described in 
detail elsewhere31 and at www.coloncfr.org. Between 1997 and 2012, the Colon Cancer 
Family Registry recruited families via: population-based probands who were recently 
diagnosed colorectal cancer cases from state or regional population cancer registries in the 
USA (Washington, California, Arizona, Minnesota, Colorado, New Hampshire, North 
Carolina, and Hawaii), Australia (Victoria) and Canada (Ontario); and clinic-based probands 
who were enrolled from multiple-case families referred to family cancer clinics in the USA 
(Mayo Clinic, Rochester, Minnesota, and Cleveland Clinic, Cleveland, Ohio), Canada 
(Ontario), Australia (Melbourne, Adelaide, Perth, Brisbane, Sydney) and New Zealand 
(Auckland). Probands were asked for permission to contact their relatives to seek their 
enrolment in the Cancer Family Registry. For population-based families, first-degree 
relatives of probands were recruited and recruitment was extended to more distant relatives 
by some registries. For clinic-based families, recruitment was based on availability but 
attempts were made to recruit up to second-degree relatives of affected individuals (detailed 
in Newcomb et al.31). Informed consent was obtained from all study participants, and the 
study protocol was approved by the institutional research ethics review board at each 
registry.
Data Collection
Information on demographics, personal characteristics, personal and family history of 
cancer, cancer-screening history, history of polyps, polypectomy, and other surgeries was 
obtained by questionnaires from all probands and participating relatives. Participants were 
followed approximately every 5 years after baseline to update this information. For the 
present study, each individual’s lifetime cancer history was based on the most recent data 
(baseline or most recent follow-up). Reported cancer diagnoses and age at diagnosis were 
confirmed using pathology reports, medical records, cancer registry reports, and death 
certificates, where possible. We collected family history of cancer from all participants, thus 
may obtain multiple reports on a single individual. If so and reports conflict or vary, we used 
the specific protocol of algorithms for selecting reports of cancer. For example, in Australia 
reports of cancer were selected over reports of no cancer, detailed dates of death/birth are 
selected over estimates, and relative sources were selected as follows (in the hierarchy): self-
report; the spouse or partner; a parent or adult son/daughter; brother or sister; grandparent or 
grandchild; aunt, uncle, nephew or niece; cousin; other. The tumour anatomic location and 
histology were coded and stored using the International Classification of Diseases for 
Oncology (ICD-O).32 We attempted to obtain blood samples from all participants and 
tumour tissue samples from participants affected with colorectal cancer.
MUTYH mutation testing
As previously described by Cleary et al.,3 genomic DNA extracted from each proband was 
tested for 12 previously identified MUTYH variants: c.536A>G p.(Tyr179Cys), c.1187G>A 
p.(Gly396Asp), c.312C>A p.(Tyr104Ter), c.821G>A p.(Arg274Gln), c.1438G>T p.
(Glu480Ter), c.1171C>T p.(Gln391Ter), c.1147delC p.(Ala385ProfsTer23), c.933+3A>C p.
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(Gly264TrpfsX7), c.1437_1439delGGA p.(Glu480del), c.721C>T, p.(Arg241Trp), c.
1227_1228dup p.(Glu410GlyfsX43), and c.1187-2A>G p.(Leu397CysfsX89) using the 
MassArray MALDI-TOF Mass Spectrometry (MS) system (Sequenom, San Diego, CA). To 
confirm the MUTYH mutation and identify additional mutations, screening of the entire 
MUTYH coding region, promoter, and splice site regions was performed on all samples 
exhibiting MS mobility shifts using denaturing high-performance liquid chromatography 
(Transgenomic Wave 3500HT System; Transgenomic, Omaha, NE). All MS-detected 
variants and WAVE mobility shifts were submitted for sequencing for mutation confirmation 
(ABI PRISM 3130XL Genetic Analyser). That is, if a heterozygous MUTYH mutation was 
identified, then the MUTYH gene was screened for any additional mutations not captured by 
the Sequenom genotyping screen to ensure all potential compound heterozygous carriers 
were identified. The relatives of probands with a pathogenic MUTYH germline mutation 
underwent testing for the specific variant identified in the proband.
Statistical Analysis
The median, range, mean, and standard deviation of the ages at cancer diagnoses were 
calculated using Stata 13.0 (StataCorp, College Station, TX, 2013). Hazard ratios (HRs), i.e. 
the age-, sex- and country-specific cancer incidence for carriers divided by that for the 
general population, were estimated for each cancer site. Age- and sex-specific cancer 
incidences in 1988–1992 for each country (the USA, Canada and Australia) were obtained 
from Cancer Incidence in Five Continents.33 The period of 1988–1992 was selected for 
analysis because it was the closest available dataset to the mean calendar year of cancer 
diagnoses in the sample. We used a modified segregation analysis,34, 35 (as described in 
detail in the Appendix of Dowty et al.36). This analytical method is not subject to population 
stratification, can be rigorously adjusted for ascertainment and uses data on all study 
participants, whether genotyped or not, thereby maximising statistical power. Models were 
fitted by the method of maximum likelihood with the statistical package MENDEL 3.2.37
For each cancer site, the age at cancer diagnosis was modelled as a random variable whose 
hazard was the relevant population incidence rate multiplied by a site-specific HR. 
Observation time for each individual started at birth and ended at first diagnosis of any 
cancer, last follow-up or death, whichever occurred first. Where age at diagnosis of a cancer 
was not reported (22% of all cancer cases), we assumed the age of diagnosis to be the 
median age at that cancer diagnosis for the general population obtained from SEER Cancer 
Statistics Review (1975–2008).38
Estimates were appropriately adjusted for the clinic- and population-based ascertainment of 
families using a combination of retrospective likelihood and ascertainment-corrected joint 
likelihood,35, 39, 40 in which each pedigree’s data was conditioned on the proband’s 
genotype, cancer status and age of onset (for population-based families) or on the proband’s 
genotype and the affected statuses and ages of onset of all family members at the time of 
ascertainment, i.e. when the proband was found to be a MUTYH mutation carrier (for clinic-
based families). Our estimates are therefore the parameter values which maximize the 
conditional likelihood of the observed data conditioned on the relevant ascertainment 
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criteria. Our estimates are unaffected by the selective ascertainment of families into our 
study.
Estimated cumulative risks (penetrance) of cancers to age 70 years and corresponding 95% 
CIs for MUTYH mutation carriers were calculated for each sex from the HR estimates and 
the age- and sex-specific USA population incidences incidencei at age i using the formula:
The total number of carriers was estimated by summing MUTYH carrier probabilities for all 
individuals, as calculated from Mendel’s laws of inheritance, the known genetic relationship 
of each individual to his or her genotyped relatives and a population allele frequency of 
0.0085 (but not any affected statuses).26 These calculations were performed using R 2.15.041 
and a modified version of Mendel 3.2.37
RESULTS
We identified 276 probands who were known to carry germline mutations in the MUTYH 
gene from the Colon Cancer Family Registry. We excluded 10 probands who were also 
known to carry a pathogenic germline mutation in a DNA mismatch repair gene (Lynch 
syndrome).42 Of the remaining 266 probands, 41 (15%) were biallelic MUTYH mutation 
carriers and 225 (85%) were monoallelic MUTYH mutation carriers. Of these, 91% (n = 
241) were Caucasians and 9% (n = 25) were others (9 African Americans, 5 Latinos, 2 
Native Americans, 1 Portuguese and 8 unknown). 237 (89%) probands were ascertained via 
population-based resources (Figure 1). There were 140 (53%) families recruited from the 
USA, 81 (30%) from Canada, and 45 (17%) from Australia and New Zealand. The MUTYH 
variants of the probands are shown in Supplementary Table 1. Of the 12 MUTYH variants 
examined, 73% of biallelic MUTYH mutations were compound heterozygous or 
homozygous p.(Tyr179Cys) or p.(Gly396Asp) mutations. Similarly, 92% of monoallelic 
MUTYH mutations were either p.(Tyr179Cys) or p.(Gly396Asp).
We obtained data on a total of 1,903 (929 female) first-degree relatives and 3,255 (1,623 
female) second-degree relatives of the 266 probands. MUTYH mutation status was tested for 
290 relatives (13 were found to be biallelic mutation carriers, 138 were monoallelic mutation 
carriers, and 139 were non-carriers). We estimated that there were additional 40 biallelic and 
1,874 monoallelic mutation carriers among non-genotyped relatives, giving a total estimated 
number of 53 biallelic and 2,012 monoallelic mutation-carrying relatives in our study 
sample.
Table 1 shows the numbers and mean ages of diagnoses of cancers at various sites in the 
affected first- and second-degree relatives (combined) of the probands. Of these cancer 
diagnoses in the relatives, 17% were verified by pathology report, medical clinical records, 
cancer registry reports and/or death certificates (Supplementary Table 2).
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Biallelic MUTYH mutation carriers had urinary bladder cancer incidence 19 (95% CI, 3.7–
97) times and ovarian cancer incidence 17 (95% CI, 2.4–115) times higher than the general 
population. Monoallelic MUTYH mutation carriers had gastric cancer incidence 9.3 (95% 
CI, 6.7–13) times and hepatobiliary cancer incidence 4.5 (95% CI, 2.7–7.5) times higher 
than the general population. Monoallelic MUTYH mutation carriers also had a slightly 
higher incidence of endometrial cancer (HR, 2.1; 95% CI, 1.1–3.9) and breast cancer (HR, 
1.4; 95% CI, 1.0–2.0). We did not find evidence for an increased risk of cancers at the other 
sites that we were able to estimate HRs (kidney, pancreas, brain and prostate) (Table 2). For 
cancers at some sites (e.g., small bowel, thyroid, ureter), we were not able to estimate 
reliable HRs. A sensitivity analysis excluding all relatives with missing age at cancer 
diagnosis showed results similar to those of the main analysis (details not shown).
The estimated cumulative risks to age 70 years of specific cancer sites for carriers from the 
USA are provided in Table 2. It is estimated that 25% (95% CI, 5%–77%) and 8% (95% CI, 
2%–33%) of male and female biallelic MUTYH mutation carriers, respectively, will be 
diagnosed with urinary bladder cancer by the age of 70 years, whereas 14% (95% CI, 2%–
65%) will be diagnosed with ovarian cancer. For monoallelic MUTYH mutation carriers, 5% 
(95% CI, 4%–7%) and 2.3% (95% CI, 1.7%–3.3%) of males and females, respectively, will 
be diagnosed with gastric cancer while 3% (95% CI, 2%–5%) and 1.4% (95% CI, 0.8%–
2.3%), respectively, will be diagnosed with hepatobiliary cancer. Of female monoallelic 
MUTYH mutation carriers, 3% (95% CI, 2%–6%) will develop endometrial cancer and 11% 
(95% CI, 8%–16%) will develop breast cancer (Table 2). The corresponding cumulative 
risks for carriers living in Canada and Australia are given in Supplementary Table 3.
DISCUSSION
We have estimated the risk of extracolonic cancers for biallelic and monoallelic MUTYH 
mutation carriers, mostly Caucasians, using one of the world’s largest resources of these 
carriers.
We estimated that biallelic MUTYH mutation carriers had a 19-fold increased risk of urinary 
bladder cancer and a 17-fold increased risk of ovarian cancer, compared with the general 
population. This is consistent with a previous study by Vogt et al.12, which found an 
increased risk of urinary bladder cancer (standardized incidence ratio [SIR], 7.2; 95% CI, 
2.0–18.4) and ovarian cancer (SIR, 5.7; 95% CI, 1.2–16.7). These estimates are not 
statistically different from our estimates (p=0.34 and p=0.37, respectively, based on the 
method proposed by Altman and Bland43). Cancer screening guidelines for carriers of 
biallelic mutations in MUTYH currently only address cancer of the colon and upper 
gastrointestinal tracts.44-46 Although our study confirms the previous report of Vogt et al.12 
of increased risks of bladder and ovarian cancers for biallelic mutation carriers, it may be too 
early to advise clinicians to consider implementing early detection at these sites given the 
wide confidence intervals around our estimates as well as the lack of evidence for the 
efficacy of screening methods for these cancers.47, 48 Further, our study was unable to 
examine previous suggestions that biallelic mutations in MUTYH increase the susceptibility 
to duodenal,7, 12, 17, 18 breast,12, 19 endometrial,10, 13 and gastric18 cancer, possibly because 
of the small numbers of cases of these cancers in our study sample.
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For monoallelic MUTYH mutation carriers, we found an increased risk of gastric and liver 
cancers, as well as a slightly increased risk of endometrial and breast cancers. In the current 
analysis, we observed only a slightly elevated risk of breast cancer, consistent with previous 
reports.27-29 For example, in a population-based case-control study of Jewish descendants of 
North African origin, Rennert et al. reported an elevated risk of breast cancer for carriers of 
a MUTYH p.(Gly396Asp) variant (odds ratio [OR] = 1.86, 95% CI 1.02–3.39).28 In a 
Chinese case-control study, Zu et al. reported an association between AluYb8 insertion in 
MUTYH and a modest increased risk of breast cancer (OR = 1.26, 95% CI 1.01–1.56) 
although we did not test for this variant in our study.29 Wasielewski et al. also reported a 
higher frequency of monoallelic MUTYH mutations in families with both breast and 
colorectal cancer compared with the population (4.1% vs. 1.9%).27 Other studies failure to 
find evidence for an increased risk of breast cancer for monoallelic mutation carriers may be 
due to the lack of power given the modest increase in the risk of breast cancer and the small 
sample sizes.11, 20
The wide confidence intervals for some cancer risks observed in the present study are due to 
limited sample size and/or variability in risk due to genetic heterogeneity or the influence of 
environmental risk factors. This is especially seen in our estimates for urinary bladder and 
ovarian cancer risks for biallelic mutation carriers. In a previous study, we have shown a 
substantial variation in colorectal cancer risks using a polygenic model that mimics the 
effect of a large number of cancer-susceptibility loci, in additional to the MUTYH mutation 
effect.6 To our knowledge, thus far the only study conducted to investigate environmental 
modifiers of colorectal cancer risk for MUTYH mutation carriers was on the relationship 
with hormone replacement therapy,5 which reported no evidence of interaction between 
hormone replacement therapy and MUTYH mutations.
The strengths of the study are the relatively large sample size (although the numbers of the 
biallelic mutation carriers were small), established registry with up to 15 years of follow-up, 
and its multinational populations (increasing generalizability). This study avoided potential 
survival bias as deceased cases were represented using methods that estimated carrier 
probabilities based on the genetic relationship of the deceased and untested individuals to 
their confirmed carrier and non-carrier relatives. Furthermore, ascertainment bias (due to 
inclusion of relatives’ cancers that resulted in ascertainment of the family) was avoided in 
this study as estimates were appropriately adjusted for the clinic- and population-based 
ascertainment of families.
A potential limitation of our study is that self-reported unverified cancer cases in the 
relatives (83%) may affect the accuracy of estimates. However, the majority of our families 
were recruited from population cancer registries (89%) and we tested their MUTYH 
mutation status after surveying family history. Therefore, any measurement error (under- or 
over-reporting) of family history of cancer will be non-differential with respect of mutation 
status and our results comparing cancer risks for carriers with the general population is 
likely to be attenuated. Further, previous studies showed a high probability of agreement 
between proband-reported cancer status in first-degree relatives and the validated report; for 
example, 95.4% (95% CI, 92.6-98.3) for female breast cancer, 83.3% (95% CI, 72.8-93.8) 
for ovarian cancer; and 79.3% (95% CI, 70.0-88.6) for prostate cancer.49 We systematically 
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attempted to estimate HR for each cancer site separately for monoallelic and biallelic 
mutation carriers. However, for many sites there were insufficient numbers of cancer 
diagnosis to generate reasonable estimates of HR. Because of many more relatives of 
monoallelic mutation carriers compared with biallelic mutation carriers (225 vs. 41 
families), we were able to estimate the risk of more cancer sites for monoallelic mutation 
carriers while we were only able to estimate the cancer risk of two sites (urinary bladder and 
ovary) for biallelic mutation carriers. Further, we did not have sufficient power to examine 
cancer risks associated with specific variants of the MUTYH gene in our study. Some 
studies have reported associations of specific MUTYH variants with particular disease types 
and severity. For example, monoallelic or biallelic mutation carriers of a MUTYH p.
(Tyr179Cys) variant had a higher risk of colorectal cancer than carriers of a MUTYH p.
(Gly396Asp) variant.5, 6 Our results might have limited relevance for non-Caucasian 
populations, since our cohort was comprised mainly of individuals with MUTYH variants 
that commonly occur in Caucasians, and there are ethnic and geographical differences in 
MUTYH variants.50 Finally, most of the relatives included in the study (including those 
affected with a cancer) were not tested for their mutation status, leading to less precise 
estimates than if every relative was genetically tested, so our estimates should be replicated 
in larger studies to obtain more precise estimates.
In summary, we found that biallelic MUTYH mutation carriers are at increased risks of 
developing urinary bladder and ovarian cancers and monoallelic carriers are at increased 
risks of gastric, liver, breast, and endometrial cancers. Further studies investigating cancer 
risks and disease characteristics associated with specific MUTYH mutation variants are 
warranted.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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NOVELTY AND IMPACT STATEMENT
People with a biallelic mutation in MUTYH are at increased risks of developing urinary 
bladder and ovarian cancers and people with a monoallelic mutation are at increased risks 
of gastric, liver, breast, and endometrial cancers. This information will be useful for their 
clinical management.
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Selection of study sample
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Table 1
Numbers and mean ages at diagnosis of extracolonic cancers in the first- and second-degree relatives 
(combined) of probands
Male (n=2,552) Female (n=2,606)
Site of cancer N Mean age (SD) N Mean age (SD)
Stomach 27 68.4 (9.39) 26 73.2 (12.5)
Hepatobiliary tract 15 62.1 (12.9) 10 72.9 (8.37)
Brain 10 57.9 (12.7) 12 54.0 (12.1)
Urinary bladder 4 66.0 (10.7) 5 78.4 (12.3)
Renal pelvis/Kidney 6 64.7 (11.3) 9 66.4 (12.0)
Pancreas 4 64.1 (10.3) 6 72.0 (11.2)
Small bowel 0 1 52
Ureter 1 59 0
Thyroid 1 29 4 41.0 (17.3)
Pharynx 9 62.7 (6.71) 6 69.0 (9.54)
Esophagus 7 63.8 (8.22) 2 72.0 (1.41)
Lung 46 63.7 (12.6) 15 62.7 (10.0)
Bone 7 67.3 (18.7) 4 55.5 (19.7)
Ovary 10 52.7 (12.8)
Endometrium 22 66.1 (14.0)
Breast 106 60.7 (12.0)
Cervix 5 37.4 (12.1)
Prostate 63 69.4 (8.41)
N, total number of affected relatives; SD, standard deviation
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Table 2
Hazard ratios and corresponding cumulative risks % to age 70 years of extracolonic cancers for carriers of 
germline monoallelic and biallelic mutations in MUTYH
Site of cancer HR (95% CI)*
Cumulative risk % (95% CI)**
Males Females
Biallelic carriers
Urinary bladder 19 (3.7–97) 25 (5.4–77) 7.6 (1.5–33)
Ovary 17 (2.4–115) 14 (2.2–65)
Monoallelic carriers
Stomach 9.3 (6.7–13) 5.0 (3.6–6.9) 2.3 (1.7–3.3)
Hepatobiliary tract 4.5 (2.7–7.5) 2.9 (1.7–4.7) 1.4 (0.8–2.3)
Endometrium 2.1 (1.1–3.9) 3.3 (1.8–6.2)




Renal pelvis/Kidney 2.3 (0.1–3.1)
Pancreas 2.3 (0.2–4.1)
CI, confidence interval; HR, hazard ratio
*
HR was provided for both males and females combined given that HRs were not different by sex.
**
Cumulative risks were estimated only for cancers that were significantly associated with MUTYH mutations. These cumulative risks were 
calculated for carriers of germline monoallelic and biallelic mutations in MUTYH living in USA. See Supplementary Table 3 for cumulative risks 
for carriers living in Canada and Australia.
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